Catalytic Asymmetric Hydrogenation of N-Boc-Imidazoles and Oxazoles
摘要:
Substituted imidazoles and oxazoles were respectively hydrogenated into the corresponding chiral imidazolines and oxazolines (up to 99% ee). The highly enantioselective hydrogenation was achieved by using the chiral ruthenium catalyst, which is generated from Ru(eta(3)-methallyl)(2)(cod) and a trans-chelating chiral bisphosphine ligand, PhTRAP. This is the first successful catalytic asymmetric reduction of 5-membered aromatic rings containing two or more heteroatoms.
Catalytic Asymmetric Hydrogenation of N-Boc-Imidazoles and Oxazoles
摘要:
Substituted imidazoles and oxazoles were respectively hydrogenated into the corresponding chiral imidazolines and oxazolines (up to 99% ee). The highly enantioselective hydrogenation was achieved by using the chiral ruthenium catalyst, which is generated from Ru(eta(3)-methallyl)(2)(cod) and a trans-chelating chiral bisphosphine ligand, PhTRAP. This is the first successful catalytic asymmetric reduction of 5-membered aromatic rings containing two or more heteroatoms.
Enantioselective Aminohydroxylation of Styrenyl Olefins Catalyzed by an Engineered Hemoprotein
作者:Inha Cho、Christopher K. Prier、Zhi‐Jun Jia、Ruijie K. Zhang、Tamás Görbe、Frances H. Arnold
DOI:10.1002/anie.201812968
日期:2019.3.4
Chiral 1,2‐aminoalcohols are widely represented in biologically active compounds from neurotransmitters to antivirals. While many synthetic methods have been developed for accessing aminoalcohols, the direct aminohydroxylation of alkenes to unprotected, enantioenriched aminoalcohols remains a challenge. Using directed evolution, we have engineered a hemoprotein biocatalyst based on a thermostable